Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myriad gains gene testing rights in dispute with OncorMed

This article was originally published in Clinica

Executive Summary

Myriad will be the only company in the US providing genetic testing for the breast and ovarian cancer genes BRCA1 and BRCA2, following an early settlement with OncorMed in their legal dispute over patent rights. OncorMed will withdraw from testing services for the BRCA1&2 genes and hand over the business to Myriad for an undisclosed fee.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT081487

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel